


PHARMACEUTICAL 2019

RVL Pharmaceuticals plc Rank 88 of 371







PHARMACEUTICAL 2019



RVL Pharmaceuticals plc Rank 88 of 371



The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 182% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -3.6%, being 328% points above the market average of -331%.

| Input Variable | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current | 172,385 |
| Cost of Goods Sold | 135,014 |
| Intangible Assets | 591,245 |
| Liabilities, Current | 114,394 |
| Liabilities, Non-Current | 266,803 |
| Other Assets | 752 |
| Other Compr. Net Income | -1,213 |
| Other Expenses | 94,953 |
| Other Liabilities | 28,179 |
| Other Net Income | -20,126 |
| Property and Equipment | 31,263 |
| Research and Development | 48,761 |
| Revenues | 263,701 |
| Selling, General and Administrative Expense | 74,243 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 795,645 |
| Liabilities | 409,376 |
| Expenses | 352,971 |
| Stockholders Equity | 386,269 |
| Net Income | -109,396 |
| Comprehensive Net Income | -110,003 |
| Economic Capital Ratio | -3.6% |